The lipid triad in type 2 diabetes - Prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes

被引:42
|
作者
Temelkova-Kurktschiev, T
Hanefeld, M
机构
[1] Tech Univ Dresden, Zentrum Klin Studien, Forschungsbereich Endokrinol & Stoffwechsel, D-01307 Dresden, Germany
[2] Tech Univ Dresden, Ctr Clin Studies, D-01307 Dresden, Germany
关键词
hypertriglyceridaemia; high-density lipoprotein cholesterol; atherosclerosis; type; 2; diabetes; metabolic syndrome;
D O I
10.1055/s-2004-815753
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease is the major cause of morbidity and mortality in type 2 diabetes mellitus. Among the established risk factors, the lipid triad (elevated triglycerides, decreased high-density lipoprotein cholesterol, and small dense low-density lipoprotein cholesterol) is a powerful risk factor for atherosclerosis in type 2 diabetes. The prevalence of hypertriglyceridaemia (HTG) in type 2 diabetes is two to three times higher than in non-diabetics. The Copenhagen Male study, the AMORIS study, and several other trials showed hypertriglyceridaemia to be an independent predictor of coronary heart disease (CHD). HTG may promote risk both directly and indirectly through association with alterations of lipoprotein size and composition. The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) demonstrated that raising high-density lipoprotein cholesterol (HDL-C) in patients with low (HDL-C) and low-density lipoprotein cholesterol (LDL-C) is associated with a significant reduction in CHD risk. It was shown in the Diabetes Intervention Study, AFCAPS/TexCAPS, and PROCAM studies that decreased HDL-C and elevated triglycerides are independent risk factors for atherosclerosis, particularly in patients with diabetes mellitus. Several epidemiological studies demonstrated that total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratios or low-density lipoprotein cholesterol/high-density lipoprotein cholesterol (LDL-C/HDL-C) ratios could be better predictors of atherosclerosis than any single lipid parameter. Intima-media thickness (IMT), a well established marker of early atherosclerosis, is associated with HTG/low HDL-cholesterol. In the Risk factors in IGT for Atherosclerosis and Diabetes (RIAD) study total and HDL-cholesterol were independent determinants of IMT in subjects at risk for type 2 diabetes. Postprandial HTG was also shown to be correlated with increased IMT in type 2 diabetic patients.
引用
收藏
页码:75 / 79
页数:5
相关论文
共 50 条
  • [1] Beyond low-density lipoprotein: Addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome
    Nesto R.W.
    American Journal of Cardiovascular Drugs, 2005, 5 (6) : 379 - 387
  • [2] Glycation of high-density lipoprotein in type 2 diabetes mellitus
    SUN Jia-teng
    SHEN Ying
    Lü An-kang
    LU Lin
    SHEN Wei-feng
    中华医学杂志(英文版), 2013, 126 (21) : 4162 - 4165
  • [3] High-Density Lipoprotein Alterations in Type 2 Diabetes and Obesity
    Denimal, Damien
    Monier, Serge
    Bouillet, Benjamin
    Verges, Bruno
    Duvillard, Laurence
    METABOLITES, 2023, 13 (02)
  • [4] Glycation of high-density lipoprotein in type 2 diabetes mellitus
    Sun Jia-teng
    Shen Ying
    Lu An-kang
    Lu Lin
    Shen Wei-feng
    CHINESE MEDICAL JOURNAL, 2013, 126 (21) : 4162 - 4165
  • [5] Low prevalence of type 2 diabetes mellitus among patients with high levels of high-density lipoprotein cholesterol
    Juren, Andrew J.
    Sarwal, Gautamn
    Al-Sarraf, Ahmad
    Vrablik, Michal
    Chan, Darren
    Humphries, Karin H.
    Frohlich, Jiri J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (03) : 194 - 198
  • [6] Evaluation of Dysfunctional High-Density Lipoprotein in Patients With Type 2 Diabetes
    Murakami, Hiroshi
    Matsumura, Koki
    Yamashita, Maki
    Matsuki, Kota
    Tanabe, Jutaro
    Murakami, Hiroshi
    Matsui, Jun
    Tamasawa, Naoki
    Suda, Toshihiro
    DIABETES, 2012, 61 : A129 - A129
  • [7] Effect of Alirocumab in Individuals with Type 2 Diabetes and High Triglycerides and Low High-Density Lipoprotein Cholesterol
    Colhoun, Helen M.
    Leiter, Lawrence A.
    Muller-Wieland, Dirk
    Cariou, Bertrand
    Ray, Kausik K.
    Tinahones, Francisco
    Domenger, Catherine
    Letierce, Alexia
    Israel, Marc
    del Prato, Stefano
    DIABETES, 2019, 68
  • [8] Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
    Helen M. Colhoun
    Lawrence A. Leiter
    Dirk Müller-Wieland
    Bertrand Cariou
    Kausik K. Ray
    Francisco J. Tinahones
    Catherine Domenger
    Alexia Letierce
    Marc Israel
    Rita Samuel
    Stefano Del Prato
    Cardiovascular Diabetology, 19
  • [9] Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
    Colhoun, Helen M.
    Leiter, Lawrence A.
    Mueller-Wieland, Dirk
    Cariou, Bertrand
    Ray, Kausik K.
    Tinahones, Francisco J.
    Domenger, Catherine
    Letierce, Alexia
    Israel, Marc
    Samuel, Rita
    Del Prato, Stefano
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [10] High-Density Lipoprotein at the Interface of Type 2 Diabetes Mellitus And Cardiovascular Disorders
    Van Linthout, Sophie
    Spillmann, Frank
    Schultheiss, Heinz-Peter
    Tschoepe, Carsten
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (13) : 1504 - 1516